Conference Correspondent

Ibrutinib in Relapsed/Refractory CLL After Allogeneic Stem-Cell Transplant

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Dinaciclib plus Ofatumumab in Patients with Relapsed/Refractory CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Ibrutinib versus Ofatumumab in Patients with Relapsed/Refractory CLL in the RESONATE Study

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

The FCR2 Regimen: A Phase 2 Study of FCR-Lite and Lenalidomide in Frontline CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Idelalisib plus Rituximab for Relapsed CLL: Interim Analysis in Subpopulations with del17p and Other Adverse Prognostic Factors

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

The RESONATE-17 Trial: Efficacy and Safety of Ibrutinib in Patients with Relapsed/Refractory CLL and del17p

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Interim Analysis of Phase 2 ICLL01: Ofatumumab and High-Dose Methylprednisolone in Patients at Highest Risk for Relapsed/Refractory CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

ONO-4059: A New Oral, Selective BTK Inhibitor for Patients with High-Risk CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Results from the CLL11 Study: Salvage Therapy with Obinutuzumab plus Chlorambucil in Patients with CLL and Comorbidities

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Dose De-Escalation in Fit, Older Patients with CLL: Balancing Efficacy, Safety, and Tolerability

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Page 32 of 44

29
30
31
32
33
34
35